Next-generation probiotics: the spectrum from probiotics to live biotherapeutics (Q87909855)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28440276%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

title

Next-generation probiotics: the spectrum from probiotics to live biotherapeutics (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28440276%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28440276%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Julian R Marchesi

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28440276%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Colin Hill

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28440276%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

publication date

25 April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28440276%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28440276%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28440276%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

page(s)

17057

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28440276%20AND%20SRC:MED&resulttype=core&format=json

Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic

18 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Statement on the update of the list of QPS-recommended biological agents intentionally added to food or feed as notified to EFSA. 2: Suitability of taxonomic units notified to EFSA until March 2015

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Patent watch: Modulating the human microbiome with live biotherapeutic products: intellectual property landscape

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

A novel strain of Bacteroides fragilis enhances phagocytosis and polarises M1 macrophages

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

The Bacteroides fragilis toxin fragilysin disrupts the paracellular barrier of epithelial cells

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Substrate cleavage profiling suggests a distinct function of Bacteroides fragilis metalloproteinases (fragilysin and metalloproteinase II) at the microbiome-inflammation-cancer interface

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Preliminary safety evaluation of a new Bacteroides xylanisolvens isolate

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Impact of oral consumption of heat-treated Bacteroides xylanisolvens DSM 23964 on the level of natural TFα-specific antibodies in human adults

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

IgA production in the large intestine is modulated by a different mechanism than in the small intestine: Bacteroides acidifaciens promotes IgA production in the large intestine by inducing germinal center formation and increasing the number of IgA+

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Inhibition of the cytotoxic effect of Clostridium difficile in vitro by Clostridium butyricum MIYAIRI 588 strain

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Effect of Clostridium butyricum on fecal flora in Helicobacter pylori eradication therapy

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Cholesterol-lowering effect of Clostridium butyricum in cholesterol-fed rats

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Effect of Clostridium butyricum on the formation and dissolution of gallstones in experimental cholesterol cholelithiasis

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Clostridium butyricum MIYAIRI 588 shows antitumor effects by enhancing the release of TRAIL from neutrophils through MMP-8.

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Faecalibacterium prausnitzii A2-165 has a high capacity to induce IL-10 in human and murine dendritic cells and modulates T cell responses.

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Faecalibacterium prausnitzii inhibits interleukin-17 to ameliorate colorectal colitis in rats

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Food-Grade Bacteria Expressing Elafin Protect Against Inflammation and Restore Colon Homeostasis

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Oral administration of an IL-10-secreting Lactococcus lactis strain prevents food-induced IgE sensitization

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

AG013, a mouth rinse formulation of Lactococcus lactis secreting human Trefoil Factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis.

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Recombinant Lactococcus lactis can make the difference in antigen-specific immune tolerance induction, the Type 1 Diabetes case

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Engineering of the gut commensal bacterium Bacteroides ovatus to produce and secrete biologically active murine interleukin-2 in response to xylan.

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Xylan-regulated delivery of human keratinocyte growth factor-2 to the inflamed colon by the human anaerobic commensal bacterium Bacteroides ovatus.

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Treatment of colitis with a commensal gut bacterium engineered to secrete human TGF-β1 under the control of dietary xylan 1.

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Identification and use of the putative Bacteroides ovatus xylanase promoter for the inducible production of recombinant human proteins

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Advancing probiotic research in humans in the United States: Challenges and strategies

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Medicines from microbiota

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Duodenal infusion of donor feces for recurrent Clostridium difficile

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

From stool transplants to next-generation microbiota therapeutics

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Specific humoral immune response to the Thomsen-Friedenreich tumor antigen (CD176) in mice after vaccination with the commensal bacterium Bacteroides ovatus D-6

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Bacteroides sp. strain D8, the first cholesterol-reducing bacterium isolated from human feces

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Effect of probiotics on postoperative quality of gastric bypass surgeries: a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

The role of intestinal bacteria in gallstone formation in animal model. A study on biliary lipid composition and bile acid profiles in bile, small intestinal contents and feces of clostridium butyricum Miyairi No. 588 monocontaminated mice

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Safety assessment of the Clostridium butyricum MIYAIRI 588® probiotic strain including evaluation of antimicrobial sensitivity and presence of Clostridium toxin genes in vitro and teratogenicity in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Effects of active egg white product/ Clostridium butyricum Miyairi 588 additive on peripheral leukocyte populations in periparturient dairy cows

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

[Inhibition of enteropathogens by Clostridium butyricum MIYAIRI 588]

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Effects of orally administered Clostridium butyricum MIYAIRI 588 on mucosal immunity in mice

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Sequence analysis of a bacteriocinogenic plasmid of Clostridium butyricum and expression of the bacteriocin gene in Escherichia coli

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI.

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Clostridium butyricum MIYAIRI 588 improves high-fat diet-induced non-alcoholic fatty liver disease in rats.

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

The effect of probiotic treatment with Clostridium butyricum on enterohemorrhagic Escherichia coli O157:H7 infection in mice

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Induction of peroxisomes by butyrate-producing probiotics

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

The effect of Clostridium butyricum MIYAIRI on the prevention of pouchitis and alteration of the microbiota profile in patients with ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Emerging evidence of the role of gut microbiota in the development of allergic diseases

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Faecalibacterium prausnitzii subspecies-level dysbiosis in the human gut microbiome underlying atopic dermatitis.

1 reference

https://api.crossref.org/works/10.1038%2FNMICROBIOL.2017.57

7 January 2021

Molecular characterization of the fragilysin pathogenicity islet of enterotoxigenic Bacteroides fragilis.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28440276

12 December 2020

inferred from PubMed ID database lookup

Effect of probiotics on serum bile acids in patients with ulcerative colitis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28440276

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1038/NMICROBIOL.2017.57

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28440276%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference